Abbott Laboratories (ABT) Short-term Investments (2009 - 2026)

Abbott Laboratories has disclosed Short-term Investments across 18 years of filings, most recently posting $499.0 million for Q2 2026.

• In Q2 2026, Short-term Investments rose 50.76% year-over-year to $499.0 million; the TTM figure through Jun 2026 stood at $499.0 million (up 50.76% YoY), while the FY2025 annual figure was $417.0 million, up 18.8% from the prior year.
• Short-term Investments came in at $499.0 million for Q2 2026 at Abbott Laboratories, up from $492.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $499.0 million in Q2 2026 to a low of $222.0 million in Q3 2025.
• Average Short-term Investments over 5 years is $350.1 million, with a median of $344.5 million recorded in 2023.
• Year-over-year, Short-term Investments plunged 36.0% in 2022 and soared 57.69% in 2026.
• Over 5 years, Short-term Investments stood at $288.0 million in 2022, then soared by 32.99% to $383.0 million in 2023, then retreated by 8.36% to $351.0 million in 2024, then increased by 18.8% to $417.0 million in 2025, then rose by 19.66% to $499.0 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $499.0 million in Q2 2026, $492.0 million in Q1 2026, and $417.0 million in Q4 2025.